Association between pharmacokinetics of lenvatinib in healthy subjects and genetic polymorphisms of ABCB1 3435C>T and ABCB1 2677G>T/A

References

• Bazett HC. 1920. An analysis of time relations of the electrocardiogram. Heart. 7:353–370.
   Google Scholar
• Boss DS, Glen H, Beijnen JH, Keesen M, Morrison R, Tait B, Copalu W, Mazur A, Wanders J, O'Brien JP, et al. 2012. A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer. 106(10):1598–1604.
   PubMed Web of Science ®Google Scholar
• Brambila-Tapia AJ. 2013. MDR1 (ABCB1) polymorphisms: functional effects and clinical implications. Rev Invest Clin. 65(5):445–454.
   PubMedGoogle Scholar
• Cabanillas ME, Habra MA. 2016. Lenvatinib: Role in thyroid cancer and other solid tumors. Cancer Treat Rev. 42:47–55.
   PubMed Web of Science ®Google Scholar
• Dubbelman AC, Rosing H, Nijenhuis C, Huitema AD, Mergui-Roelvink M, Gupta A, Verbel D, Thompson G, Shumaker R, Schellens JH, et al. 2015. Pharmacokinetics and excretion of (14)C-lenvatinib in patients with advanced solid tumors or lymphomas. Invest New Drugs. 33(1):233–240.
   PubMed Web of Science ®Google Scholar
• Dubbelman AC, Rosing H, Thijssen B, Gebretensae A, Lucas L, Chen H, Shumaker R, Schellens JH, Beijnen JH. 2012. Development and validation of LC-MS/MS assays for the quantification of E7080 and metabolites in various human biological matrices. J Chromatogr B Analyt Technol Biomed Life Sci. 887–888:25–34.
   PubMed Web of Science ®Google Scholar
• Hussein Z, Mizuo H, Hayato S, Namiki M, Shumaker R. 2017. Clinical pharmacokinetic and pharmacodynamic profile of lenvatinib, an orally active, small-molecule, multitargeted tyrosine kinase inhibitor. Eur J Drug Metab Pharmacokinet. 42(6):903–914.
   PubMed Web of Science ®Google Scholar
• ICH Harmonized Tripartite Guideline E14. 2005. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. USA: Center for Drug Evaluation and Research.
   Google Scholar
• Ikuta K, Yano S, Trung VT, Hanibuchi M, Goto H, Li Q, Wang W, Yamada T, Ogino H, Kakiuchi S, et al. 2009. E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles. Clin Cancer Res. 15(23):7229–7237.
   PubMed Web of Science ®Google Scholar
• Inoue K, Asai N, Mizuo H, Fukuda K, Kusano K, Yoshimura T. 2012. Unique metabolic pathway of [(14)C]lenvatinib after oral administration to male cynomolgus monkey. Drug Metab Dispos. 40(4):662–670.
   PubMed Web of Science ®Google Scholar
• Karch FE, Lasagna L. 1977. Toward the operational identification of adverse drug reactions. Clin Pharmacol Ther. 21(3):247–254.
   PubMed Web of Science ®Google Scholar
• Li J, Wang X, Ning C, Wang Z, Wang Y, Zheng M, Zhang S, Lu Y, Zhang Y, Li N, et al. 2020. Influences of ABC transporter and CYP3A4/5 genetic polymorphisms on the pharmacokinetics of lenvatinib in Chinese healthy subjects. Eur J Clin Pharmacol. 76(8):1125–1133.
   PubMed Web of Science ®Google Scholar
• Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M. 2008. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res. 14(17):5459–5465.
   PubMed Web of Science ®Google Scholar
• Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T, Uenaka T, Asada M. 2008. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 122(3):664–671.
   PubMed Web of Science ®Google Scholar
• Okamoto K, Kodama K, Takase K, Sugi NH, Yamamoto Y, Iwata M, Tsuruoka A. 2013. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett. 340(1):97–103.
   PubMed Web of Science ®Google Scholar
• Ozeki T, Nagahama M, Fujita K, Suzuki A, Sugino K, Ito K, Miura M. 2019. Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer. Sci Rep. 9(1):5405.
   Web of Science ®Google Scholar
• Sadhasivam S, Chidambaran V. 2012. Pharmacogenomics of opioids and perioperative pain management. Pharmacogenomics. 13(15):1719–1740.
   PubMed Web of Science ®Google Scholar
• Saiz-Rodríguez M, Belmonte C, Román M, Ochoa D, Jiang-Zheng C, Koller D, Mejía G, Zubiaur P, Wojnicz A, Abad-Santos F. 2018. Effect of ABCB1 C3435T polymorphism on pharmacokinetics of antipsychotics and antidepressants. Basic Clin Pharmacol Toxicol. 123(4):474–485.
   PubMed Web of Science ®Google Scholar
• Shumaker R, Aluri J, Fan J, Martinez G, Ren M, Chen K. 2014. Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers. Int J Clin Pharmacol Ther. 52(4):284–291.
   PubMed Web of Science ®Google Scholar
• Shumaker R, Aluri J, Fan J, Martinez G, Thompson GA, Ren M. 2014. Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults. Clin Drug Investig. 34(9):651–659.
   PubMed Web of Science ®Google Scholar
• Shumaker R, Aluri J, Fan J, Martinez G, Thompson GA, Ren M. 2015. Effects of ketoconazole on the pharmacokinetics of lenvatinib (e7080) in healthy participants. Clin Pharmacol Drug Dev. 4(2):155–160.
   PubMed Web of Science ®Google Scholar
• Takahashi N, Miura M, Scott SA, Kagaya H, Kameoka Y, Tagawa H, Saitoh H, Fujishima N, Yoshioka T, Hirokawa M, et al. 2010. Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia. J Hum Genet. 55(11):731–737.
   PubMed Web of Science ®Google Scholar
• Takashina Y, Naito T, Mino Y, Yagi T, Ohnishi K, Kawakami J. 2012. Impact of CYP3A5 and ABCB1 gene polymorphisms on fentanyl pharmacokinetics and clinical responses in cancer patients undergoing conversion to a transdermal system. Drug Metab Pharmacokinet. 27(4):414–421.
   PubMed Web of Science ®Google Scholar
• Yamada K, Yamamoto N, Yamada Y, Nokihara H, Fujiwara Y, Hirata T, Koizumi F, Nishio K, Koyama N, Tamura T. 2011. Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. Clin Cancer Res. 17(8):2528–2537.
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Matsui J, Matsushima T, Obaishi H, Miyazaki K, Nakamura K, Tohyama O, Semba T, Yamaguchi A, Hoshi SS, et al. 2014. Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell. 6:18.
   PubMedGoogle Scholar